NYSE · TAK
Healthcare · Drug Manufacturers - Specialty & Generic
$18.03
Down-$0.03 (-0.17%)
Updated Aug 31, 2026, 2:03 PM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TAK closed at $18.03 after 20 trading sessions, up 7.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $18.00 | $18.11 | $17.96 | $18.03 | 1.81M |
| Aug 27, 2026 | $18.21 | $18.22 | $17.971 | $18.03 | 1.73M |
| Aug 26, 2026 | $18.32 | $18.38 | $18.2191 | $18.23 | 2.33M |
| Aug 25, 2026 | $18.21 | $18.355 | $18.21 | $18.35 | 1.25M |
| Aug 24, 2026 | $18.24 | $18.26 | $18.11 | $18.24 | 2.23M |
| Aug 21, 2026 | $18.09 | $18.245 | $18.08 | $18.18 | 1.48M |
| Aug 20, 2026 | $18.25 | $18.34 | $18.105 | $18.13 | 2.23M |
| Aug 19, 2026 | $18.22 | $18.495 | $18.22 | $18.34 | 3.31M |
| Aug 18, 2026 | $17.86 | $18.16 | $17.8341 | $18.05 | 3.81M |
| Aug 17, 2026 | $17.40 | $17.4398 | $17.28 | $17.38 | 2.47M |
| Aug 14, 2026 | $17.50 | $17.66 | $17.48 | $17.63 | 3.14M |
| Aug 13, 2026 | $17.47 | $17.47 | $17.36 | $17.39 | 1.95M |
| Aug 12, 2026 | $17.36 | $17.47 | $17.35 | $17.41 | 2M |
| Aug 11, 2026 | $17.38 | $17.635 | $17.36 | $17.48 | 2.34M |
| Aug 10, 2026 | $17.48 | $17.61 | $17.42 | $17.55 | 4.17M |
| Aug 7, 2026 | $17.48 | $17.56 | $17.405 | $17.45 | 4.25M |
| Aug 6, 2026 | $17.07 | $17.275 | $16.91 | $17.02 | 4.27M |
| Aug 5, 2026 | $16.66 | $16.78 | $16.57 | $16.72 | 4.87M |
| Aug 4, 2026 | $16.35 | $16.681 | $16.30 | $16.56 | 5.91M |
| Aug 3, 2026 | $17.19 | $17.22 | $16.83 | $16.83 | 3.15M |
The latest Smart Investors Daily articles mentioning TAK.
TAK research
Company profile and research snapshot.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 11, 2020 | JP Morgan | Overweight | — |
| Nov 1, 2019 | Cowen & Co. | Market Perform | — |
| Sep 24, 2019 | Jefferies | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 24, 2026
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1)Landmark Phase 3 Studies Demonstrated Significant and
Benzinga · Aug 13, 2026
Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more human-relevant methods.
Benzinga · Aug 10, 2026
https://sam.gov/opp/b8e3db55feb04369933f735cc6cda9aa/view
SeekingAlpha · Aug 7, 2026
Takeda Pharmaceutical remains a hold, with shares near 52-week highs and uncertainty about a major successor to Entyvio. Click to read this TAK stock update.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TAK.
